RFA-DK-19-013: NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
Internal Deadline: Contact Office of Research if interested.
LOI: October 21, 2019
External Deadline: November 21, 2019
Award Information: Type: Grant
Estimated Number of Awards: 1
Anticipated Amount: Up to $1,000,000 per year for up to 5 years.
Budgetary Requirements: N/A
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
- CV – (5 pages maximum)
Who May Serve as PI: The HCCC Director is required to have an established record of external funding and research accomplishment but is not required to have a background in nonmalignant hematology research.
The objective of the NIDDK Hematology Centers Program is to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and/or to study normal hematopoiesis. It aims to provide state-of-the-art equipment, resources and expertise, and serve as a national resource for nonmalignant hematology research, including enhancing the research of scientists just beginning their careers in the field and attracting established investigators from other domains.
The NIDDK Hematology Centers Program will consist of up to four Cooperative Centers of Excellence in Hematology (CCEHs) and a Hematology Central Coordinating Center (HCCC). The overall goal of the HCCC is to organize and facilitate the activities of the NIDDK Hematology Centers Program, including development, support, and execution of a Pilot and Feasibility Program. The NIDDK CCEHs are comprised of Biomedical Research Cores, an Administrative Core, and an Enrichment Program. Usually, three to five Biomedical Research Cores are included in a CCEH.
Objectives and Scope
The overall goal of the HCCC is to organize and facilitate the activities of the NIDDK Hematology Centers Program, under the direction of the NIDDK Hematology Centers Program Steering Committee, to achieve the following objectives:
- Facilitate sharing of resources and data within the NIDDK Hematology Centers Program and with the wider nonmalignant hematology research community,
- Develop a multipronged communication plan for disseminating the information about the research resources and methods offered through the CCEHs to the wider nonmalignant hematology research community,
- Support and facilitate the education and outreach activities of the NIDDK Hematology Centers Program,
- Develop, support and execute the Pilot and Feasibility (P&F) Program to encourage junior investigators in the nonmalignant hematology field and to attract established investigators from other domains who bring in new technologies and approaches,
- Develop and manage a program-wide website for internal and external communication,
- Plan, organize and support at least one annual face-to-face meeting for the NIDDK Hematology Centers Program, including investigators supported by the P&F Program and an External Evaluation Panel,
- Provide centralized administrative support, including coordination of any relevant agreements (e.g., data use, material transfer, etc.) across the Program, and
- Schedule and coordinate web-based conference calls and webinars.
Research areas addressed by projects supported by the NIDDK Hematology Centers Program, including the P&F Program, must be in line with the research mission of the NIDDK Hematology program (see https://www.niddk.nih.gov/about-niddk/research-areas/hematologic-diseases). Some examples of these research areas are:
- Molecular and cellular biology of hematopoiesis and hematopoietic stem cell (HSC) biology, including ex vivo expansion of HSCs, definition of the niche in which HSCs thrive and relationships (cross-talk) between components of the niche and HSCs
- Hematopoietic growth factors and erythropoietin
- Use of primitive and/or definitive stem cells, including induced pluripotent stem cells (iPSCs) as a resource to study gene and cell therapy tools for hematopoietic disorders, or to use hematopoietic stem cells as cell therapy tools for other disorders (non-hematopoietic)
- Use of NIH-approved human embryonic stem cell (hESC) lines to explore development into primitive and/or definitive (adult) HSCs and their use for cell therapy
- Expressed erythroid molecular biological components and creation of reagents useful for study of the erythroid cell lineages
- Blood cell receptor biology and signaling
- Computational biology approaches to accurately predict effects of distortion in a biochemical network
- Blood cell metabolism; membrane biology and ion transport; heme metabolism; responses to environmental fluxes
- Globin biosynthesis, including its genetic regulation and its control for therapeutic purposes
- Iron absorption, storage and metabolism; pathophysiology of iron overload, and strategies for therapeutic intervention
- Development of approaches and techniques for gene therapy using hematopoietic cells
Visit our Institutionally Limited Submission webpage for updates and other announcements.